

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(10) **DK/EP 3496743 T3**

(12) **Oversættelse af
europæisk patentskrift**

-
- (51) Int.Cl.: **A 61 K 38/50 (2006.01)** **A 61 K 39/00 (2006.01)** **A 61 P 35/00 (2006.01)**
C 07 K 16/28 (2006.01) **C 12 N 9/78 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2022-04-04**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2022-02-09**
- (86) Europæisk ansøgning nr.: **17840420.8**
- (86) Europæisk indleveringsdag: **2017-09-08**
- (87) Den europæiske ansøgnings publiceringsdag: **2019-06-19**
- (86) International ansøgning nr.: **US2017050816**
- (87) Internationalt publikationsnr.: **WO2018032020**
- (30) Prioritet: **2016-08-08 US 201662372092 P** **2017-06-23 US 201762524286 P**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **AERase, Inc., 901 S. Mopac Expressway , Barton Oaks Plaza One, Suite 250, Austin, TX 78746, USA**
- (72) Opfinder: **LOWE, David, 8524 Parismina Lane, Austin, TX 78735, USA**
ROWLINSON, Scott, W., 700 Grey Fox Court, Austin, TX 78746, USA
ALTERS, Susan, 3372 Kipling Street, Palo Alto, CA 94306, USA
AGNELLO, Giulia, 203 W. 39th Street, Apt. 305, Austin, TX 78751-5023, USA
- (74) Fuldmægtig i Danmark: **Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, Danmark**
- (54) Benævnelse: **Sammensætninger og fremgangsmåder til behandling af cancer med arginindepletering og immunonkologiske midler**
- (56) Fremdragne publikationer:
WO-A1-2016/033555
WO-A2-2012/061015
WO-A2-2015/164743
US-A1- 2012 177 628
US-A1- 2016 161 485
CASEY AGER ET AL: "31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two", ILLIAJOURNAL FOR IMMUNOTHERAPY OF C, BIOMED CENTRAL LTD, LONDON, UK, vol. 4, no. 1, 16 November 2016 (2016-11-16), pages 107-221, XP021241441, DOI: 10.1186/S40425-016-0173-6
Giulia Agnello ET AL: "Abstract 3964: Reducing systemic arginine with arginase (AEB1102) therapy does not suppress the immune response induced by anti-PD-1 and anti-PD-L1, and exerts an additive anti-tumor and synergistic survival benefit | Cancer Research", Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl): Abstract nr 3964, 1 April 2017 (2017-04-01), XP055661525, DOI: 10.1158/1538-7445.AM2017-3964 Retrieved from

Fortsættes ...

the Internet: URL:https://cancerres.aacrjournals.org/content/77/13_Supplement/3964 [retrieved on 2020-01-24]

MELISSA M PHILLIPS ET AL: "+ Targeting Arginine-Dependent Cancers with Arginine-Degrading Enzymes: Opportunities and Challenges", *CANCER RES TREAT*, vol. 45, 1 January 2013 (2013-01-01), pages 251-262, XP055477608, DOI: 10.4143/crt.2013.45.4.251

KRISTIN J. LASTWIKA ET AL: "Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer", *CANCER RESEARCH*, vol. 76, no. 2, 4 December 2015 (2015-12-04), pages 227-238, XP055600222, US ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-14-3362

VIRGINIA A. PEDICORD ET AL: "Friends Not Foes: CTLA-4 Blockade and mTOR Inhibition Cooperate during CD8 + T Cell Priming To Promote Memory Formation and Metabolic Readiness", *THE JOURNAL OF IMMUNOLOGY*, vol. 194, no. 5, 26 January 2015 (2015-01-26), pages 2089-2098, XP055384632, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1402390

DESCRIPTION

BACKGROUND OF THE INVENTION

[0001] It has been recognized for over 50 years that certain tumor cells have a high demand for amino acids, such as L-arginine and are killed under conditions of L-arginine depletion (Wheatley and Campbell, 2002). In human cells L-arginine is synthesized in three steps; first L-citrulline is synthesized from L-ornithine and carbamoyl phosphate by the enzyme ornithine transcarbamylase (OTC), argininosuccinate synthetase (ASS) converts L-citrulline and aspartate to argininosuccinate, followed by conversion of argininosuccinate to L-arginine and fumarate by argininosuccinate lyase (ASL). A large number of hepatocellular carcinomas (HCC), melanomas and, renal cell carcinomas (Ensor et al., 2002; Feun et al., 2007; Yoon et al., 2007) do not express ASS and thus are sensitive to L-arginine depletion. The molecular basis for the lack of ASS expression appears to be diverse and includes aberrant gene regulation. Whereas non-malignant cells enter into quiescence (G0) when depleted of L-arginine and thus remain viable for several weeks, tumor cells have cell cycle defects that lead to the re-initiation of DNA synthesis even though protein synthesis is inhibited, in turn resulting in major imbalances and rapid cell death (Shen et al., 2006; Scott et al., 2000). The selective toxicity of L-arginine depletion for HCC, melanoma and other ASS-deficient cancer cells has been extensively demonstrated in vitro, in xenograft animal models and in clinical trials (Ensor et al., 2002; Feun et al., 2007; Shen et al., 2006; Izzo et al., 2004). Recently Cheng et al. (2007) demonstrated that many HCC cells are also deficient in ornithine transcarbamylase expression and thus, they are also susceptible to enzymatic L-arginine depletion.

[0002] There is interest in the use of L-arginine hydrolytic enzymes for cancer therapy, especially the treatment of cancers such as hepatocarcinomas, melanomas and renal cell carcinomas, for example, which are common forms of cancer associated with high morbidity. Two L-arginine degrading enzymes have been used for cancer therapy: bacterial arginine deiminase and human arginases. Unfortunately, both of these enzymes display significant shortcomings that present major impediments to clinical use (immunogenicity, and low catalytic activity with very poor stability in serum, respectively). Thus, the therapeutic success of L-arginine depletion therapy will rely on addressing these shortcomings.

[0003] Another challenge in the treatment of many cancers is the ability of some cancers to evade the immune system. Some tumors, for example, do this through the immune checkpoint pathways, which are inhibitory pathways in the immune system that maintain self-tolerance by modulating immune response. These pathways can be dysregulated by tumors resulting in immune resistance. Some of these pathways, both agonists of prostimulatory receptors or antagonists of inhibitory signals, both of which result in amplification of antigen-specific T-cell responses, have become targets for cancer immunotherapy. Some exemplary receptors and ligands include cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), programmed cell death 1 (PD1), programmed cell death ligand 1 (PDL1), lymphocyte activation gene 3 (LAG3), B7-H3,

B-7-H4, and T cell membrane protein 3 (TIM3) among others. (Pardoll, 2012).

SUMMARY OF THE INVENTION

[0004] An aspect of the present disclosure relates to a pharmaceutical composition comprising a human Arginase I enzyme comprising a cobalt cofactor and an immuno-oncology agent for use in a method of inhibiting tumor growth in a subject, wherein the immune-oncology agent is selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-OX40 antibody, and an anti-OX40L antibody. In some embodiments, the cancer is one that does not express, or is otherwise deficient in, argininosuccinate synthetase (ASS), ornithine transcarbamylase (OTC), or argininosuccinate lyase (ASL).

[0005] Human Arginase I proteins used in the present disclosure have two Mn (II) sites; either or both sites can be substituted so as to generate a modified Arginase I protein with a cobalt cofactor. In some embodiments, the protein displays a k_{cat}/K_M greater than $400 \text{ mM}^{-1} \text{ s}^{-1}$ at pH 7.4. In a particular embodiment, the protein displays a k_{cat}/K_M between $400 \text{ mM}^{-1} \text{ s}^{-1}$ and $4,000 \text{ mM}^{-1} \text{ s}^{-1}$ at pH 7.4. In another embodiment, the protein displays a k_{cat}/K_M between $400 \text{ mM}^{-1} \text{ s}^{-1}$ and $2,500 \text{ mM}^{-1} \text{ s}^{-1}$ at pH 7.4 at 37° C . In a particular embodiment, the present disclosure contemplates a protein comprising an amino acid sequence of human Arginase I and a cobalt cofactor, wherein said protein exhibits a k_{cat}/K_M greater than $400 \text{ mM}^{-1} \text{ s}^{-1}$ at 37° C , pH 7.4.

[0006] The present disclosure relates to the composition defined above for the treatment of cancer or tumors by arginine depletion in conjunction with an immunotherapeutic treatment targeting an immune checkpoint pathway. Arginine depletion is accomplished with administration of a human Arginase I enzyme comprising a cobalt cofactor that exhibits at least an additive or synergistic effect when administered with an immune checkpoint targeted therapy.

[0007] The present disclosure can be described in certain embodiments as a pharmaceutical composition including a therapeutic amount of a human Arginase I enzyme comprising a cobalt cofactor and an immuno-oncology agent selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-OX40 antibody, and an anti-OX40L antibody for use in a method of inhibiting tumor growth in a subject. The tumor can be of various types that respond to arginine depletion therapy and in certain embodiments is an arginine auxotrophic tumor, or includes arginine dependent or auxotrophic cells. In certain embodiments the auxotrophic cells exhibit a reduced or inhibited expression of one or more of ASS, OTC, ASL, or a combination thereof, thus requiring the tumor cell to utilize arginine from the serum.

[0008] In certain embodiments the human Arginase I or other enzyme is stabilized by association with a stabilizing agent in order to increase the half-life of the enzyme in the serum

of a patient. As used herein "association" can include any of a number of types of association including, but not limited to covalent or non-covalent bonds, and can also include a protein fusion expressed from an engineered nucleic acid construct, from a hydrogen bonding or hydrophobic interaction and others known to those of skill in the art. Stabilizing agents for use in the disclosed methods comprise polyethylene glycol, often referred to as pegylation, conjugation to one or more homogenous synthetic protein polymers, referred to as extenylation and commercially available under the trade name Xten[®], conjugation to one or more Fc fragments or to a serum protein like albumin, for example. All such stabilized enzymes and others that would occur to those of skill in this art are contemplated by the present disclosure.

[0009] The disclosed compositions for use are applicable to both human and non-human animal subjects including but not limited to veterinary, agricultural, domestic or research animals. It is an aspect of the disclosure that the immuno-oncology agent enhances the subject's immune response. In certain embodiments enhancing an immune system includes increasing activity of a patient's T-cell response to the presence of a tumor. In certain embodiments, therefore, the immuno-oncology agent inhibits an immune suppressor, which is sometimes a cell surface receptor referred to as a checkpoint inhibitor, or a ligand for such a receptor. The immuno-oncology agent is a PD-1 pathway inhibitor selected from an anti-PD-1 antibody or an anti-PD-L1 antibody or a OX40 (CD 134) pathway inhibitor selected from an anti-OX40 or anti-OX40L (CD252) antibody Exemplary antibodies include but are not limited to pembrolizumab, atezolizumab or nivolumab.

[0010] The compositions of the disclosure are contemplated for the treatment of any responsive cancer or tumor, including, but not limited to hepatocellular carcinoma, renal cell carcinoma, breast cancer, melanoma, prostate cancer, pancreatic cancer, bladder cancer, colon carcinoma, colorectal cancer, triple negative breast cancer, Hodgkin's lymphoma, gastric cancer, glioblastoma, Merkel cell carcinoma, lung carcinoma, small cell lung cancers or non-small cell lung cancers. The administration of a combination of the human Arginase I enzyme and the anti- PD-1 antibody or anti-PDL-1 antibody, anti-OX40 antibody, or anti-OX40L antibody can exhibit an additive effect on tumor growth inhibition compared to the tumor growth inhibition exhibited by administering a therapeutic dose of the anti-PD-1 antibody alone or the anti-PD-L1 antibody, anti-OX40 antibody, and an anti-OX40L antibody alone, or the human Arginase I enzyme alone, or in certain embodiments exhibits a greater than additive, or synergistic effect on the tumor growth or cancer. The two treatment regimens can be administered concurrently or they can be administered sequentially as needed.

[0011] The current disclosure can also be described in certain embodiments as a combination for use in the treatment of cancer in a cancer patient wherein the combination comprises a pharmaceutical composition comprising a pegylated human Arginase I enzyme comprising a cobalt cofactor and an immune system modulating therapy comprising a pharmaceutical composition comprising an immuno-oncology agent selected from an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-OX40 antibody or an anti-OX40L antibody, wherein:

the pharmaceutical composition comprising a pegylated human Arginase I enzyme comprising a cobalt cofactor and the pharmaceutical composition comprising the immuno-oncology agent are administered concurrently; or

the pharmaceutical composition comprising a human Arginase I enzyme comprising a cobalt cofactor and the pharmaceutical composition comprising an immuno-oncology agent are administered sequentially.

[0012] In certain embodiments a therapeutic amount of the pegylated human Arginase I enzyme comprising a cobalt cofactor is from about 0.01 mg/kg to about 7.5 mg/kg, about 0.05 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 5 mg/kg, or any amount derivable from or contained within the preceding ranges.

[0013] The pharmaceutical composition including a pegylated human Arginase I enzyme comprising a cobalt cofactor can be administered parenterally, or it can be delivered by various routes known in the art, including but not limited to topically, subcutaneously, intravenously, intradermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrapleurally, intratracheally, intraocularly, intranasally, intravitreally, intravaginally, intrarectally, intramuscularly, subcutaneously, subconjunctivally, intravesicularly, mucosally, intrapericardially, intraumbilically, orally, by inhalation, by injection, by infusion, by continuous infusion, by localized perfusion bathing target cells directly, via a catheter, or via a lavage. In certain embodiments the pharmaceutical composition is administered intravenously or subcutaneously.

[0014] When the pharmaceutical compositions and combinations are used for the treatment of cancers, the therapeutic effect of treatment may be additive as compared to treatment with the human Arginase I enzyme alone or with said checkpoint pathway inhibitor alone, or the therapeutic effect of treatment with said human Arginase I enzyme and a checkpoint pathway inhibitor is synergistic as compared to treatment the Arginase I enzyme alone or said checkpoint pathway inhibitor alone. In certain embodiments the treatment can result in from 50% to 99%, or from 90% to 99% reduction in serum arginine in the patient, or reduction of serum arginine in a patient to an undetectable level.

[0015] . The human Arginase I enzymes can be recombinant human enzymes or engineered human enzymes.

[0016] In some embodiments, the native arginase is modified only by the substitution of the metal cofactor. In other embodiments, the arginase is modified by substitution of the metal cofactor in addition to other modifications, such as substitutions, deletions, truncations, or stabilization by conjugation to a stabilizing protein or polymer, such as by pegylation. In a particular embodiment, the invention provides a protein comprising a native amino acid sequence of human Arginase I and a cobalt cofactor, wherein the amino acid sequence is lacking part of the native sequence. In some embodiments, the arginase lacks a portion of the

wild-type sequence. In other embodiments, the amino acid sequence comprises a truncated Arginase I sequence.

[0017] In a particular embodiment, the native arginase lacks an N-terminal methionine.

[0018] In another aspect, the present disclosure contemplates an arginase I protein comprising at least one amino acid substitution, wherein the protein displays an increased catalytic activity under physiological conditions and especially at the pH of human serum (pH 7.4) when compared with native human Arginase I protein. The arginase protein is a human Arginase I protein which comprises a Co^{2+} cofactor. Substitution of the Mn^{2+} cofactor with Co^{2+} results in marked increase in catalytic activity and a drastic reduction in K_M at physiological pH. In some aspects, the present disclosure also contemplates fusion proteins comprising an arginase linked to a non-arginase amino acid sequence. In one embodiment, the non-arginase sequence comprises at least a portion of the Fc region of an immunoglobulin, e.g., to increase the half-life of the arginase in serum when administered to a patient. The Fc region or portion thereof may be any suitable Fc region. In one embodiment, the Fc region or portion thereof is an IgG Fc region. The amino acid sequence having arginase activity is a native or mutated amino acid sequence of human Arginase I comprising a cobalt cofactor. In certain embodiments, a dimeric Fc-arginase fusion protein, albumin, or a synthetic protein conjugation is contemplated.

[0019] The arginase I in the fusion protein may be native or mutated. In some embodiments, the arginase I may contain deletions, substitutions, truncations or a combination thereof. In a particular embodiment, the present disclosure contemplates an Fc-arginase I containing fusion protein. In one embodiment, the arginase I lacks a portion of the wild-type sequence. In another embodiment, the arginase is Arginase I lacking an N-terminal methionine. The arginase further comprises a cobalt cofactor. Either or both sites can be substituted to generate a fusion protein comprising an amino acid sequence of human Arginase I and a cobalt cofactor. In some embodiments, the arginase contains a substitution. Exemplary arginase enzymes for use in the present disclosure are more fully described in U.S. Patent No. 8,440,184.

[0020] The present disclosure relates to compositions and combinations for use in treating subjects with cancer. In some embodiments, the cancer is one that does not express, or is otherwise deficient in, ASS, OTC, or ASL. In particular embodiments, the human cancer is an arginine auxotrophic cancer. As discussed above, the arginase protein may be native, mutated, and/or otherwise modified, e.g., metal cofactor modified. In one embodiment, the present disclosure contemplates a pharmaceutical composition or a combination for use in treating a human cancer patient, the treatment comprising administering a composition comprising a fusion protein as described above and an immuno-oncology agent selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-OX40 antibody, and an anti-OX40L antibody. In some embodiments, the administration occurs under conditions such that at least a portion of the cancer cells of the cancer are killed. In another embodiment, the formulation comprises an amino acid sequence having human arginase

activity higher than that displayed by the authentic human arginases at physiological conditions and further comprising one or more attached polyethylene glycol chain(s). In some embodiment, the formulation is a pharmaceutical formulation comprising any of the above discussed arginase proteins and a pharmaceutically acceptable excipient. Such pharmaceutically acceptable excipients are well known to those having skill in the art. All of the above arginase variants are contemplated as useful for human therapy.

[0021] The cancer may be any type of cancer or tumor type. In some embodiments, the cancer is hepatocellular carcinoma, renal cell carcinoma, melanoma, prostate cancer, or pancreatic cancer. In some embodiments, the formulation is administered topically, intravenously, intradermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrapleurally, intratracheally, intraocularly, intranasally, intravitreally, intravaginally, intrarectally, intramuscularly, subcutaneously, subconjunctival, intravesicularly, mucosally, intrapericardially, intraumbilically, orally, by inhalation, by injection, by infusion, by continuous infusion, by localized perfusion bathing target cells directly, via a catheter, or via a lavage.

[0022] All of the above mentioned arginases, variants and the like are contemplated in a preferred embodiment as purified or isolated proteins, and preferably monomeric proteins.

[0023] The embodiments in the Example section are understood to be embodiments of the invention that are applicable to all aspects of the invention.

[0024] The use of the term "or" in the claims is used to mean "and/or" unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and "and/or."

[0025] Throughout this application, the term "about" is used to indicate that a value includes the standard deviation of error for the composition, device or method being employed to determine the value.

[0026] Following long-standing patent law, the words "a" and "an," when used in conjunction with the word "comprising" in the claims or specification, denotes one or more, unless specifically noted.

[0027] The term "therapeutically effective" as used herein refers to an amount of an active agent and/or therapeutic composition (such as a therapeutic polynucleotide and/or therapeutic polypeptide) that is employed in methods of the present disclosure to achieve a therapeutic effect, such as wherein at least one symptom of a condition being treated is at least ameliorated, and/or to the analysis of the processes or materials used in conjunction with these cells.

[0028] Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed

description and the specific examples, while indicating specific embodiments of the disclosure are given by way of illustration only.

BRIEF DESCRIPTION OF THE FIGURES

[0029] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure. The disclosure may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

FIG. 1 is a graph showing serum L-arginine depletion in the mouse model. Serum L-Arg concentrations of Balb/c mice treated with a single IP dose of Co-hArgI are kept \leq to 3-4 μ M for over 3 days.

FIG. 2 is a graph showing HCC tumor xenograft reduction when treated with Co-hArgI as compared to controls. Nude mice bearing a Hep3b tumor xenografts were treated twice by IP injection with either PBS (\circ) or Co-hArgI (\bullet) at day 9 and at day 12. Tumor shrinkage was observed in the mice treated with Co-hArgI whereas PBS treated tumors grew unchecked.

FIG. 3 is a graph showing the effect of cobalt loading on the catalytic activity of human Arginase I.

FIG. 4 is a graph showing colon carcinoma tumor growth inhibition in CT26 mouse model with Co-hArgI, anti PD-L1 and the combination of Co-hArgI and anti PD-L1. As seen in the data, the combination of the 2 agents has a greater than additive effect on inhibition of tumor growth.

FIG. 5 is a graph showing colon carcinoma tumor growth inhibition in an MC38 mouse model with Co-hArgI, anti OX40 antibodies, and the combination of Co-hArgI and anti OX40 antibodies. As seen in the data, the combination of the 2 agents has a greater than additive effect on inhibition of tumor growth.

FIG. 6 is a graph showing CD45+ Tcells present in CT26 mouse model with Co-hArgI, anti PD-L1 and the combination of Co-hArgI and anti PD-L1.

FIG. 7 is a graph showing percent CD8+ cells present in CD45+ Tcells as shown in FIG. 6.

DESCRIPTION OF THE ILLUSTRATIVE EMBODIMENTS

[0030] The invention is set forth by the appended claims. The disclosure generally relates to compositions and combinations for use in the treatment of cancer comprising human Arginase I enzymes comprising a cobalt cofactor that deplete L-arginine in serum. In some embodiments, the cancer is one that does not express, or is otherwise deficient in,

argininosuccinate synthetase (ASS), ornithine transcarbamylase (OTC), or argininosuccinate lyase (ASL), or other enzymes required for arginine biosynthesis. Both native and mutated enzymes are contemplated, as well as enzymes fused to other polypeptides as well as enzymes conjugated to polymers that increase serum persistence, e.g., high molecular weight polyethylene glycol

I. Arginase

[0031] Arginase is a manganese-containing enzyme. It is the final enzyme of the urea cycle. Arginase is the fifth and final step in the urea cycle, a series of biophysical reactions in mammals during which the body disposes of harmful ammonia. Specifically, arginases convert L-arginine into L-ornithine and urea.

[0032] L-arginine is the nitrogen donating substrate for nitric oxide synthase (NOS), producing L-citrulline and NO. Although the K_M of arginase (2-5 mM) has been reported to be much higher than that of NOS for L-arginine (2-20 μ M), arginase may also play a role in regulating NOS activity. Under certain conditions Arginase I is Cys-S-nitrosylated, resulting in higher affinity for L-arginine and reduced availability of substrate for NOS.

[0033] Arginase is a homo-trimeric enzyme with an α/β fold of a parallel eight-stranded β sheet surrounded by several helices. The enzyme contains a di-nuclear metal cluster that is integral to generating a hydroxide for nucleophilic attack on the guanidinium carbon of L-arginine. The native metal for arginase is Mn^{2+} . These Mn^{2+} ions coordinate water, orientating and stabilizing the molecule and allowing water to act as a nucleophile and attack L-arginine, hydrolyzing it into ornithine and urea.

[0034] Mammals have two arginase isozymes (EC 3.5.3.1) that catalyze the hydrolysis of L-arginine to urea and L-ornithine. The Arginase I gene is located on chromosome 6 (6q.23), is highly expressed in the cytosol of hepatocytes, and functions in nitrogen removal as the final step of the urea cycle. The Arginase II gene is found on chromosome 14 (14q.24.1). Arginase II is mitochondrially located in tissues such as kidney, brain, and skeletal muscle where it is thought to provide a supply of L-ornithine for proline and polyamine biosynthesis (Lopez et al., 2005).

[0035] Arginases have been investigated for nearly 50 years as a method for degrading extracellular L-arginine (Dillon et al., 2002). Some promising clinical results have been achieved by introducing arginase by transhepatic arterial embolisation; following which, several patients experienced partial remission of HCC (Cheng et al., 2005). However, since arginase has a high K_M (~2-5 mM) and exhibits very low activity at physiological pH values, high dosing is required for chemotherapeutic purposes (Dillon et al., 2002). While native arginase is cleared from circulation within minutes (Savoca et al., 1984), a single injection of PEG-arginase MW5000 in rats was sufficient to achieve near complete arginine depletion for ~3 days (Cheng

et al., 2007).

[0036] Cheng et al. made the surprising observation that many human HCC cells lines do not express OTC (in addition to ASS) and thus they are susceptible to PEG-arginase (Cheng et al., 2007). In mice implanted with Hep3b hepatocarcinoma cells weekly administration of PEG-arginase resulted in tumor growth retardation which was accentuated by co-administration of 5-fluorouracil (5-FU). However, PEG-arginase was used at the very high doses that are impractical for human therapy, reflecting its lower physiological activity.

[0037] To address these issues a bacterial arginine hydrolyzing enzyme, arginine deiminase or ADI which displays good kinetics and stability has been tested in vitro and clinically. Unfortunately ADI is a bacterial enzyme and therefore it induces strong immune responses and adverse effects in most patients. However, for those patients who do not develop significant adverse responses, an impressive percentage exhibit stable disease or remission.

[0038] For clinical use, it is essential that the arginase is engineered to allow it to persist for long times (e.g., days) in circulation. In the absence of any modification, human arginase has a half-life of only a few minutes in circulation primarily because its size is not sufficiently large to avoid filtration through the kidneys. Unmodified human arginase is very susceptible to deactivation in serum and it is degraded with a half-life of only four hours. Therefore, the present invention developed novel and improved forms of arginase for clinical research and potential therapeutic use with improved circulation persistence.

II. Arginase Variants

[0039] Mammals have two arginase isozymes (EC 3.5.3.1) that catalyze the hydrolysis of L-arginine to urea and L-ornithine. The Arginase I gene is located on chromosome 6 (6q.23), is highly expressed in the cytosol of hepatocytes, and functions in nitrogen removal as the final step of the urea cycle. The Arginase II gene is found on chromosome 14 (14q.24.1). Arginase II is mitochondrially located in tissues such as kidney, brain, and skeletal muscle where it is thought to provide a supply of L-ornithine for proline and polyamine biosynthesis (Lopez et al., 2005). L-arginine is the sole substrate for nitric oxide synthase (NOS), producing L-citrulline and NO. Although the K_M of arginase (2-5 mM) has been reported to be much higher than that of NOS for L-arginine (2-20 μ M), arginase may also play a role in regulating NOS activity (Durante et al., 2007). Under certain conditions Arginase I is Cys-S-nitrosylated, resulting in higher affinity for L-arginine and reduced availability of substrate for NOS (Santhanam et al., 2007). Arginase is a homo-trimeric enzyme with an α/β fold of a parallel eight-stranded β -sheet surrounded by several helices. The enzyme contains a di-nuclear metal cluster that is integral to generating a hydroxide for nucleophilic attack on the guanidinium carbon of L-arginine (Cama et al., 2003; Dowling et al., 2008). The native metal for arginase is Mn^{2+} . Arginase with the native metal (i.e. Mn^{2+}) exhibits a pH optimum of 9. At physiological pH the enzyme exhibits more than a 10-fold lower k_{cat}/K_M in the hydrolysis of L-arginine. The low catalytic activity

displayed by the authentic human arginase with the native Mn^{2+} enzyme presents a problem for human therapy since it means that impractical doses of the enzyme may have to be used to achieve a therapeutically relevant reduction in L-arginine plasma levels.

[0040] The present disclosure makes use of mutant arginases wherein the natural metal cofactor (Mn^{2+}) is replaced with cobalt (Co^{2+}). Incorporation of Co^{2+} in the place of Mn^{2+} in human Arginase I or human Arginase II results in dramatically higher activity at physiological pH. It was found that a human Arginase I enzyme containing Co^{2+} ("Co-hArgI") displayed a 10 fold increase in k_{cat}/K_M in vitro at pH 7.4, which in turn translated into a 15 fold increase in HCC cytotoxicity and a 13-fold increase in melanoma cytotoxicity as compared to the human Arginase I which contains Mn^{2+} ("Mn-hArgI"). It was also found that a pharmacological preparation of Co-hArgI could clear serum L-Arg for over 3 days in mice with a single injection. Furthermore, it was found that a pharmacological preparation of Co-hArgI could shrink HCC tumor xenografts in nude mice whereas Mn-hArgI only slowed tumor growth (Ensor et al., 2002).

[0041] In certain aspects of the disclosure compositions related to pegylated arginase are disclosed. Specifically, pegylation of arginase at an engineered cysteine residue (e.g., substituting the third residue of the N-terminal) may be used to produce a homogenous pegylated arginase composition. Methods for isolation of pegylated arginase based on temporary disruption of polymerization are also disclosed.

[0042] Pegylation is the process of covalent attachment of poly(ethylene glycol) polymer chains to another molecule, normally a drug or therapeutic protein. Pegylation is routinely achieved by incubation of a reactive derivative of PEG with the target macromolecule. The covalent attachment of PEG to a drug or therapeutic protein can "mask" the agent from the host's immune system (reduced immunogenicity and antigenicity), increase the hydrodynamic size (size in solution) of the agent which prolongs its circulatory time by reducing renal clearance. Pegylation can also provide water solubility to hydrophobic drugs and proteins.

[0043] The first step in pegylation is the suitable functionalization of the PEG polymer at one or both terminals. PEGs that are activated at each terminus with the same reactive moiety are known as "homobifunctional", whereas if the functional groups present are different, then the PEG derivative is referred as "heterobifunctional" or "heterofunctional." The chemically active or activated derivatives of the PEG polymer are prepared to attach the PEG to the desired molecule.

[0044] The choice of the suitable functional group for the PEG derivative is based on the type of available reactive group on the molecule that will be coupled to the PEG. For proteins, typical reactive amino acids include lysine, cysteine, histidine, arginine, aspartic acid, glutamic acid, serine, threonine, tyrosine. The N-terminal amino group and the C-terminal carboxylic acid can also be used.

[0045] The techniques used to form first generation PEG derivatives are generally reacting the

PEG polymer with a group that is reactive with hydroxyl groups, typically anhydrides, acid chlorides, chloroformates and carbonates. In the second generation pegylation chemistry more efficient functional groups such as aldehyde, esters, amides etc. made available for conjugation.

[0046] As applications of pegylation have become more and more advanced and sophisticated, there has been an increase in need for heterobifunctional PEGs for conjugation. These heterobifunctional PEGs are very useful in linking two entities, where a hydrophilic, flexible and biocompatible spacer is needed. Preferred end groups for heterobifunctional PEGs are maleimide, vinyl sulfones, pyridyl disulfide, amine, carboxylic acids and NHS esters.

[0047] The most common modification agents, or linkers, are based on methoxy PEG (mPEG) molecules. Their activity depends on adding a protein-modifying group to the alcohol end. In some instances polyethylene glycol (PEG diol) is used as the precursor molecule. The diol is subsequently modified at both ends in order to make a hetero- or homo-dimeric PEG-linked molecule (as shown in the example with PEG bis-vinylsulfone).

[0048] Proteins are generally PEGylated at nucleophilic sites such as unprotonated thiols (cysteinyll residues) or amino groups. Examples of cysteinyll-specific modification reagents include PEG maleimide, PEG iodoacetate, PEG thiols, and PEG vinylsulfone. All four are strongly cysteinyll-specific under mild conditions and neutral to slightly alkaline pH but each has some drawbacks. The amide formed with the maleimides can be somewhat unstable under alkaline conditions so there may be some limitation to formulation options with this linker. The amide linkage formed with iodo PEGs is more stable, but free iodine can modify tyrosine residues under some conditions. PEG thiols form disulfide bonds with protein thiols, but this linkage can also be unstable under alkaline conditions. PEG-vinylsulfone reactivity is relatively slow compared to maleimide and iodo PEG; however, the thioether linkage formed is quite stable. Its slower reaction rate also can make the PEG-vinylsulfone reaction easier to control.

[0049] Site-specific pegylation at native cysteinyll residues is seldom carried out, since these residues are usually in the form of disulfide bonds or are required for biological activity. On the other hand, site-directed mutagenesis can be used to incorporate cysteinyll pegylation sites for thiol-specific linkers. The cysteine mutation must be designed such that it is accessible to the pegylation reagent and is still biologically active after pegylation.

[0050] Amine-specific modification agents include PEG NHS ester, PEG tresylate, PEG aldehyde, PEG isothiocyanate, and several others. All react under mild conditions and are very specific for amino groups. The PEG NHS ester is probably one of the more reactive agents; however, its high reactivity can make the pegylation reaction difficult to control at large scale. PEG aldehyde forms an imine with the amino group, which is then reduced to a secondary amine with sodium cyanoborohydride. Unlike sodium borohydride, sodium cyanoborohydride will not reduce disulfide bonds. However, this chemical is highly toxic and must be handled cautiously, particularly at lower pH where it becomes volatile.

[0051] Due to the multiple lysine residues on most proteins, site-specific pegylation can be a challenge. Fortunately, because these reagents react with unprotonated amino groups, it is possible to direct the pegylation to lower-pK amino groups by performing the reaction at a lower pH. Generally the pK of the α -amino group is 1-2 pH units lower than the epsilon-amino group of lysine residues. By PEGylating the molecule at pH 7 or below, high selectivity for the N-terminus frequently can be attained. However; this is only feasible if the N-terminal portion of the protein is not required for biological activity. Still, the pharmacokinetic benefits from pegylation frequently outweigh a significant loss of in vitro bioactivity, resulting in a product with much greater in vivo bioactivity regardless of pegylation chemistry.

[0052] There are several parameters to consider when developing a pegylation procedure. Fortunately, there are usually no more than four or five key parameters. The "design of experiments" approach to optimization of pegylation conditions can be very useful. For thiol-specific pegylation reactions, parameters to consider include: protein concentration, PEG-to-protein ratio (on a molar basis), temperature, pH, reaction time, and in some instances, the exclusion of oxygen. Oxygen can contribute to intermolecular disulfide formation by the protein, which will reduce the yield of the PEGylated product. The same factors should be considered (with the exception of oxygen) for amine-specific modification except that pH may be even more critical, particularly when targeting the N-terminal amino group.

[0053] For both amine- and thiol-specific modifications, the reaction conditions may affect the stability of the protein. This may limit the temperature, protein concentration, and pH. In addition, the reactivity of the PEG linker should be known before starting the pegylation reaction. For example, if the pegylation agent is only 70% active, the amount of PEG used should ensure that only active PEG molecules are counted in the protein-to-PEG reaction stoichiometry. How to determine PEG reactivity and quality will be described later.

IV. Proteins and Peptides

[0054] In certain embodiments, the present disclosure concerns novel compositions comprising at least one protein or peptide, such as stabilized arginase multimers. These peptides may be comprised in a fusion protein or conjugated to an agent as described supra.

A. Proteins and Peptides

[0055] As used herein, a protein or peptide generally refers, but is not limited to, a protein of greater than about 200 amino acids, up to a full length sequence translated from a gene; a polypeptide of greater than about 100 amino acids; and/or a peptide of from about 3 to about 100 amino acids. For convenience, the terms "protein," "polypeptide" and "peptide" are used interchangeably herein.

[0056] In certain embodiments the size of at least one protein or peptide may comprise, but is not limited to, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, about 180, about 190, about 200, about 210, about 220, about 230, about 240, about 250, about 275, about 300, about 325, about 350, about 375, about 400, about 425, about 450, about 475, about 500, about 525, about 550, about 575, about 600, about 625, about 650, about 675, about 700, about 725, about 750, about 775, about 800, about 825, about 850, about 875, about 900, about 925, about 950, about 975, about 1000, about 1100, about 1200, about 1300, about 1400, about 1500, about 1750, about 2000, about 2250, about 2500 or greater amino acid residues.

[0057] As used herein, an "amino acid residue" refers to any naturally occurring amino acid, any amino acid derivative or any amino acid mimic known in the art. In certain embodiments, the residues of the protein or peptide are sequential, without any non-amino acid interrupting the sequence of amino acid residues. In other embodiments, the sequence may comprise one or more non-amino acid moieties. In particular embodiments, the sequence of residues of the protein or peptide may be interrupted by one or more non-amino acid moieties. Accordingly, the term "protein or peptide" encompasses amino acid sequences comprising at least one of the 20 common amino acids found in naturally occurring proteins, or at least one modified or unusual amino acid, including but not limited to those shown on Table 1 below.

TABLE 1

Modified and Unusual Amino Acids	
Abbr.	Amino Acid
Aad	2-Aminoadipic acid
Baad	3-Aminoadipic acid
Bala	β -alanine, β -Amino-propionic acid
Abu	2-Aminobutyric acid
4Abu	4-Aminobutyric acid, piperidinic acid
Acp	6-Aminocaproic acid
Ahe	2-Aminoheptanoic acid
Aib	2-Aminoisobutyric acid
Baib	3-Aminoisobutyric acid
Apm	2-Aminopimelic acid
Dbu	2,4-Diaminobutyric acid
Des	Desmosine
Dpm	2,2'-Diaminopimelic acid
Dpr	2,3-Diaminopropionic acid

Modified and Unusual Amino Acids	
Abbr.	Amino Acid
EtGly	N-Ethylglycine
EtAsn	N-Ethylasparagine
Hyl	Hydroxylysine
AHyl	allo-Hydroxylysine
3Hyp	3-Hydroxyproline
4Hyp	4-Hydroxyproline
Ide	Isodesmosine
Alle	allo-Isoleucine
MeGly	N-Methylglycine, sarcosine
Melle	N-Methylisoleucine
MeLys	6-N-Methyllysine
MeVal	N-Methylvaline
Nva	Norvaline
Nle	Norleucine
Orn	Ornithine

[0058] Proteins or peptides may be made by any technique known to those of skill in the art, including the expression of proteins, polypeptides or peptides through standard molecular biological techniques, the isolation of proteins or peptides from natural sources, or the chemical synthesis of proteins or peptides. The nucleotide and protein, polypeptide and peptide sequences corresponding to various genes have been previously disclosed, and may be found at computerized databases known to those of ordinary skill in the art. One such database is the National Center for Biotechnology Information's Genbank and GenPept databases (available on the world wide web at ncbi.nlm.nih.gov/). The coding regions for known genes may be amplified and/or expressed using the techniques disclosed herein or as would be known to those of ordinary skill in the art. Alternatively, various commercial preparations of proteins, polypeptides and peptides are known to those of skill in the art.

B. Nucleic Acids and Vectors

[0059] In certain aspects of the disclosure nucleic acid sequences encoding a fusion protein as a stabilized multimeric arginase may be disclosed. Depending on which expression system to be used, nucleic acid sequences can be selected based on conventional methods. For example, human arginase I and II contain multiple codons that are rarely utilized in *E. coli* that may interfere with expression, therefore the respective genes or variants thereof may be codon optimized for *E. coli* expression. Various vectors may be also used to express the

protein of interest, such as a fusion multimeric arginase or a cysteine-substituted arginase. Exemplary vectors include, but are not limited, plasmid vectors, viral vectors, transposon or liposome-based vectors.

C. Host cells

[0060] Host cells, preferably eukaryotic cells, useful in the present disclosure are any that may be transformed to allow the expression and secretion of arginase and fusion multimers thereof. The host cells may be bacteria, mammalian cells, yeast, or filamentous fungi. Various bacteria include *Escherichia* and *Bacillus*. Yeasts belonging to the genera *Saccharomyces*, *Kluyveromyces*, *Hansenula*, or *Pichia* would find use as an appropriate host cell. Various species of filamentous fungi may be used as expression hosts including the following genera: *Aspergillus*, *Trichoderma*, *Neurospora*, *Penicillium*, *Cephalosporium*, *Achlya*, *Podospora*, *Endothia*, *Mucor*, *Cochliobolus* and *Pyricularia*.

[0061] Examples of usable host organisms include bacteria, e.g., *Escherichia coli* MC1061, derivatives of *Bacillus subtilis* BRB1 (Sibakov et al., 1984), *Staphylococcus aureus* SAI123 (Lordanescu, 1975) or *Streptococcus lividans* (Hopwood et al., 1985); yeasts, e.g., *Saccharomyces cerevisiae* AH 22 (Mellor et al., 1983) and *Schizosaccharomyces pombe*; filamentous fungi, e.g., *Aspergillus nidulans*, *Aspergillus awamori* (Ward, 1989), *Trichoderma reesei* (Penttila et al., 1987; Harkki et al, 1989).

[0062] Examples of mammalian host cells include Chinese hamster ovary cells (CHO-K1; ATCC CCL61), rat pituitary cells (GH₁; ATCC CCL82), HeLa S3 cells (ATCC CCL2.2), rat hepatoma cells (H-4-II-E; ATCC CRL 1548) SV40-transformed monkey kidney cells (COS-1; ATCC CRL 1650) and murine embryonic cells (NIH-3T3; ATCC CRL 1658). The foregoing being illustrative but not limitative of the many possible host organisms known in the art. In principle, all hosts capable of secretion can be used whether prokaryotic or eukaryotic.

[0063] Mammalian host cells expressing the arginase and/or their fusion multimers are cultured under conditions typically employed to culture the parental cell line. Generally, cells are cultured in a standard medium containing physiological salts and nutrients, such as standard RPMI, MEM, IMEM or DMEM, typically supplemented with 5-10% serum, such as fetal bovine serum. Culture conditions are also standard, e.g., cultures are incubated at 37° C. in stationary or roller cultures until desired levels of the proteins are achieved.

D. Protein Purification

[0064] Protein purification techniques are well known to those of skill in the art. These techniques involve, at one level, the homogenization and crude fractionation of the cells, tissue or organ to polypeptide and non-polypeptide fractions. The protein or polypeptide of interest

may be further purified using chromatographic and electrophoretic techniques to achieve partial or complete purification (or purification to homogeneity) unless otherwise specified. Analytical methods particularly suited to the preparation of a pure peptide are ion-exchange chromatography, gel exclusion chromatography, polyacrylamide gel electrophoresis, affinity chromatography, immunoaffinity chromatography and isoelectric focusing. A particularly efficient method of purifying peptides is fast performance liquid chromatography (FPLC) or even high performance liquid chromatography (HPLC).

[0065] A purified protein or peptide is intended to refer to a composition, isolatable from other components, wherein the protein or peptide is purified to any degree relative to its naturally-obtainable state. An isolated or purified protein or peptide, therefore, also refers to a protein or peptide free from the environment in which it may naturally occur. Generally, "purified" will refer to a protein or peptide composition that has been subjected to fractionation to remove various other components, and which composition substantially retains its expressed biological activity. Where the term "substantially purified" is used, this designation will refer to a composition in which the protein or peptide forms the major component of the composition, such as constituting about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, or more of the proteins in the composition.

[0066] Various techniques suitable for use in protein purification are well known to those of skill in the art. These include, for example, precipitation with ammonium sulphate, PEG, antibodies and the like, or by heat denaturation, followed by: centrifugation; chromatography steps such as ion exchange, gel filtration, reverse phase, hydroxylapatite and affinity chromatography; isoelectric focusing; gel electrophoresis; and combinations of these and other techniques. As is generally known in the art, it is believed that the order of conducting the various purification steps may be changed, or that certain steps may be omitted, and still result in a suitable method for the preparation of a substantially purified protein or peptide.

[0067] Various methods for quantifying the degree of purification of the protein or peptide are known to those of skill in the art in light of the present disclosure. These include, for example, determining the specific activity of an active fraction, or assessing the amount of polypeptides within a fraction by SDS/PAGE analysis. A preferred method for assessing the purity of a fraction is to calculate the specific activity of the fraction, to compare it to the specific activity of the initial extract, and to thus calculate the degree of purity therein, assessed by a "-fold purification number." The actual units used to represent the amount of activity will, of course, be dependent upon the particular assay technique chosen to follow the purification, and whether or not the expressed protein or peptide exhibits a detectable activity.

[0068] There is no general requirement that the protein or peptide always be provided in their most purified state. Indeed, it is contemplated that less substantially purified products may have utility in certain embodiments. Partial purification may be accomplished by using fewer purification steps in combination, or by utilizing different forms of the same general purification scheme. For example, it is appreciated that a cation-exchange column chromatography performed utilizing an HPLC apparatus will generally result in a greater "-fold" purification than

the same technique utilizing a low pressure chromatography system. Methods exhibiting a lower degree of relative purification may have advantages in total recovery of protein product, or in maintaining the activity of an expressed protein.

[0069] In certain embodiments a protein or peptide may be isolated or purified, for example, a stabilized arginase multimeric fusion protein, or an arginase prior or post pegylation. For example, a His tag or an affinity epitope may be comprised in such a arginase variant to facilitate purification. Affinity chromatography is a chromatographic procedure that relies on the specific affinity between a substance to be isolated and a molecule to which it can specifically bind. This is a receptor-ligand type of interaction. The column material is synthesized by covalently coupling one of the binding partners to an insoluble matrix. The column material is then able to specifically adsorb the substance from the solution. Elution occurs by changing the conditions to those in which binding will not occur (e.g., altered pH, ionic strength, temperature, etc.). The matrix should be a substance that itself does not adsorb molecules to any significant extent and that has a broad range of chemical, physical and thermal stability. The ligand should be coupled in such a way as to not affect its binding properties. The ligand should also provide relatively tight binding. And it should be possible to elute the substance without destroying the sample or the ligand.

[0070] Size exclusion chromatography (SEC) is a chromatographic method in which molecules in solution are separated based on their size, or in more technical terms, their hydrodynamic volume. It is usually applied to large molecules or macromolecular complexes such as proteins and industrial polymers. Typically, when an aqueous solution is used to transport the sample through the column, the technique is known as gel filtration chromatography, versus the name gel permeation chromatography which is used when an organic solvent is used as a mobile phase.

[0071] The underlying principle of SEC is that particles of different sizes will elute (filter) through a stationary phase at different rates. This results in the separation of a solution of particles based on size. Provided that all the particles are loaded simultaneously or near simultaneously, particles of the same size should elute together. Each size exclusion column has a range of molecular weights that can be separated. The exclusion limit defines the molecular weight at the upper end of this range and is where molecules are too large to be trapped in the stationary phase. The permeation limit defines the molecular weight at the lower end of the range of separation and is where molecules of a small enough size can penetrate into the pores of the stationary phase completely and all molecules below this molecular mass are so small that they elute as a single band.

[0072] High-performance liquid chromatography (or High pressure liquid chromatography, HPLC) is a form of column chromatography used frequently in biochemistry and analytical chemistry to separate, identify, and quantify compounds. HPLC utilizes a column that holds chromatographic packing material (stationary phase), a pump that moves the mobile phase(s) through the column, and a detector that shows the retention times of the molecules. Retention time varies depending on the interactions between the stationary phase, the molecules being

analyzed, and the solvent(s) used.

V. Pharmaceutical Compositions

[0073] It is contemplated that the arginases for use according to the present disclosure can be administered systemically or locally to inhibit tumor cell growth and, most preferably, to kill cancer cells in cancer patients with locally advanced or metastatic cancers. They can be administered intravenously, intrathecally, and/or intraperitoneally. They can be administered alone or in combination with anti-proliferative drugs. In one embodiment, they are administered to reduce the cancer load in the patient prior to surgery or other procedures. Alternatively, they can be administered after surgery to ensure that any remaining cancer (e.g. cancer that the surgery failed to eliminate) does not survive.

[0074] It is not intended that the present disclosure be limited by the particular nature of the therapeutic preparation. For example, such compositions can be provided in formulations together with physiologically tolerable liquid, gel or solid carriers, diluents, and excipients. These therapeutic preparations can be administered to mammals for veterinary use, such as with domestic animals, and clinical use in humans in a manner similar to other therapeutic agents. In general, the dosage required for therapeutic efficacy will vary according to the type of use and mode of administration, as well as the particularized requirements of individual subjects.

[0075] Such compositions are typically prepared as liquid solutions or suspensions, as injectables. Suitable diluents and excipients are, for example, water, saline, dextrose, glycerol, or the like, and combinations thereof. In addition, if desired the compositions may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, stabilizing or pH buffering agents.

[0076] Where clinical applications are contemplated, it may be necessary to prepare pharmaceutical compositions--expression vectors, virus stocks, proteins, antibodies and drugs--in a form appropriate for the intended application. Generally, pharmaceutical compositions of the present disclosure comprise an effective amount of one or more arginase variants or additional agent dissolved or dispersed in a pharmaceutically acceptable carrier. The phrases "pharmaceutical or pharmacologically acceptable" refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, such as, for example, a human, as appropriate. The preparation of a pharmaceutical composition that contains at least one arginase variant, such as a stabilized multimeric arginase or a pegylated arginase isolated by the method disclosed herein, or additional active ingredient will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington's Pharmaceutical Sciences, 18th Ed., 1990. Moreover, for animal (e.g., human) administration, it will be understood that preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biological Standards.

[0077] As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed., 1990). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the pharmaceutical compositions is contemplated.

[0078] The present invention may comprise different types of carriers depending on whether it is to be administered in solid, liquid or aerosol form, and whether it need to be sterile for such routes of administration as injection. The present disclosure can be administered intravenously, intradermally, transdermally, intrathecally, intraarterially, intraperitoneally, intranasally, intravaginally, intrarectally, topically, intramuscularly, subcutaneously, mucosally, orally, topically, locally, inhalation (e.g., aerosol inhalation), injection, infusion, continuous infusion, localized perfusion bathing target cells directly, via a catheter, via a lavage, in lipid compositions (e.g., liposomes), or by other method or any combination of the foregoing as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed., 1990).

[0079] The arginase variants may be formulated into a composition in a free base, neutral or salt form. Pharmaceutically acceptable salts, include the acid addition salts, e.g., those formed with the free amino groups of a proteinaceous composition, or which are formed with inorganic acids such as for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric or mandelic acid. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as for example, sodium, potassium, ammonium, calcium or ferric hydroxides; or such organic bases as isopropylamine, trimethylamine, histidine or procaine. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms such as formulated for parenteral administrations such as injectable solutions, or aerosols for delivery to the lungs, or formulated for alimentary administrations such as drug release capsules and the like.

[0080] Further in accordance with the present disclosure, the composition for use in the present disclosure suitable for administration is provided in a pharmaceutically acceptable carrier with or without an inert diluent. The carrier should be assimilable and includes liquid, semi-solid, i.e., pastes, or solid carriers. Except insofar as any conventional media, agent, diluent or carrier is detrimental to the recipient or to the therapeutic effectiveness of a composition contained therein, its use in administrable composition for use in practicing the methods of the present disclosure is appropriate. Examples of carriers or diluents include fats, oils, water, saline solutions, lipids, liposomes, resins, binders, fillers and the like, or combinations thereof. The composition may also comprise various antioxidants to retard oxidation of one or more component. Additionally, the prevention of the action of

microorganisms can be brought about by preservatives such as various antibacterial and antifungal agents, including but not limited to parabens (e.g., methylparabens, propylparabens), chlorobutanol, phenol, sorbic acid, thimerosal or combinations thereof.

[0081] In accordance with the present disclosure, the composition is combined with the carrier in any convenient and practical manner, i.e., by solution, suspension, emulsification, admixture, encapsulation, absorption and the like. Such procedures are routine for those skilled in the art.

[0082] In a specific embodiment of the present disclosure, the composition is combined or mixed thoroughly with a semi-solid or solid carrier. The mixing can be carried out in any convenient manner such as grinding. Stabilizing agents can be also added in the mixing process in order to protect the composition from loss of therapeutic activity, i.e., denaturation in the stomach. Examples of stabilizers for use in the composition include buffers, amino acids such as glycine and lysine, carbohydrates such as dextrose, mannose, galactose, fructose, lactose, sucrose, maltose, sorbitol, mannitol, etc.

[0083] In further embodiments, the present disclosure may concern the use of a pharmaceutical lipid vehicle compositions that include arginase variants, one or more lipids, and an aqueous solvent. As used herein, the term "lipid" will be defined to include any of a broad range of substances that is characteristically insoluble in water and extractable with an organic solvent. This broad class of compounds are well known to those of skill in the art, and as the term "lipid" is used herein, it is not limited to any particular structure. Examples include compounds which contain long-chain aliphatic hydrocarbons and their derivatives. A lipid may be naturally occurring or synthetic (i.e., designed or produced by man). However, a lipid is usually a biological substance. Biological lipids are well known in the art, and include for example, neutral fats, phospholipids, phosphoglycerides, steroids, terpenes, lysolipids, glycosphingolipids, glycolipids, sulphatides, lipids with ether and ester-linked fatty acids and polymerizable lipids, and combinations thereof. Of course, compounds other than those specifically described herein that are understood by one of skill in the art as lipids are also encompassed by the compositions and methods of the present disclosure.

[0084] One of ordinary skill in the art would be familiar with the range of techniques that can be employed for dispersing a composition in a lipid vehicle. For example, the stabilized multimeric or pegylated arginase may be dispersed in a solution containing a lipid, dissolved with a lipid, emulsified with a lipid, mixed with a lipid, combined with a lipid, covalently bonded to a lipid, contained as a suspension in a lipid, contained or complexed with a micelle or liposome, or otherwise associated with a lipid or lipid structure by any means known to those of ordinary skill in the art. The dispersion may or may not result in the formation of liposomes.

[0085] The actual dosage amount of a composition of the present disclosure administered to an animal patient can be determined by physical and physiological factors such as body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic interventions, idiopathy of the patient and on the route of administration. Depending upon the dosage and the route of administration, the number of administrations of

a preferred dosage and/or an effective amount may vary according to the response of the subject. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject.

[0086] In certain embodiments, pharmaceutical compositions may comprise, for example, at least about 0.1% of an active compound. In other embodiments, the active compound may comprise between about 2% to about 75% of the weight of the unit, or between about 25% to about 60%, for example, and any range derivable therein. Naturally, the amount of active compound(s) in each therapeutically useful composition may be prepared in such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.

[0087] In other non-limiting examples, a dose may also comprise from about 1 microgram/kg/body weight, about 5 microgram/kg/body weight, about 10 microgram/kg/body weight, about 50 microgram/kg/body weight, about 100 microgram/kg/body weight, about 200 microgram/kg/body weight, about 350 microgram/kg/body weight, about 500 microgram/kg/body weight, about 1 milligram/kg/body weight, about 5 milligram/kg/body weight, about 10 milligram/kg/body weight, about 50 milligram/kg/body weight, about 100 milligram/kg/body weight, about 200 milligram/kg/body weight, about 350 milligram/kg/body weight, about 500 milligram/kg/body weight, to about 1000 mg/kg/body weight or more per administration, and any range derivable therein. In non-limiting examples of a derivable range from the numbers listed herein, a range of about 5 mg/kg/body weight to about 100 mg/kg/body weight, about 5 microgram/kg/body weight to about 500 milligram/kg/body weight, etc., can be administered, based on the numbers described above.

VII. Definitions

[0088] The term "aa" refers to amino acid(s). Amino acid substitutions are indicated by the amino acid position, e.g. 303, in the molecule using a letter code (the letter in front of the number indicates the amino acid being replaced, while the letter after the number indicates the amino acid being introduced).

[0089] As used herein the term "portion" when in reference to a protein (as in "a portion of a given protein") refers to fragments of that protein. The fragments may range in size from four amino acid residues to the entire amino acid sequence minus one amino acid.

[0090] As used herein the terms "protein" and "polypeptide" refer to compounds comprising amino acids joined via peptide bonds and are used interchangeably.

[0091] As used herein, the term "fusion protein" refers to a chimeric protein containing the protein of interest (i.e., a human arginase or variant thereof) joined (or operably linked) to an exogenous protein fragment (the fusion partner which consists of a non-arginase protein). The fusion partner may enhance serum half-life, solubility, or both. It may also provide an affinity tag (e.g. his-tag) to allow purification of the recombinant fusion protein from the host cell or culture supernatant, or both.

[0092] The terms "in operable combination", "in operable order" and "operably linked" refer to the linkage of nucleic acid sequences in such a manner that a nucleic acid molecule capable of directing the transcription of a given gene and/or the synthesis of a desired protein molecule is produced. The term also refers to the linkage of amino acid sequences in such a manner so that a functional protein is produced.

[0093] The term " K_m " as used herein refers to the Michaelis-Menten constant for an enzyme and is defined as the concentration of the specific substrate at which a given enzyme yields one-half its maximum velocity in an enzyme catalyzed reaction.

[0094] The term k_{cat} as used herein refers to the turnover number or the number of substrate molecule each enzyme site converts to product per unit time, and in which the enzyme is working at maximum efficiency.

[0095] The term K_{cat}/K_m as used herein is the specificity constant which is a measure of how efficiently an enzyme converts a substrate into product.

[0096] The term "Mn-hArgI" refers to human Arginase I with an Mn (II) cofactor. The term "Co-hArgI" refers to human Arginase I (mutant or native) with a Co (II) cofactor.

[0097] The term " IC_{50} " is the half maximal (50%) inhibitory concentration (IC) and thus a measure of effectiveness.

[0098] The term "pegylated" refers to conjugation with polyethylene glycol (PEG), which has been widely used as a drug carrier, given its high degree of biocompatibility and ease of modification. (Harris et al., 2001). Attachment to various drugs, proteins, and liposomes has been shown to improve residence time and decrease toxicity. (Greenwald et al., 2000; Zalipsky et al., 1997). PEG can be coupled (e.g. covalently linked) to active agents through the hydroxyl groups at the ends of the chain and via other chemical methods; however, PEG itself is limited to at most two active agents per molecule. In a different approach, copolymers of PEG and amino acids have been explored as novel biomaterials which would retain the biocompatibility properties of PEG, but which would have the added advantage of numerous attachment points per molecule (providing greater drug loading), and which can be synthetically designed to suit a variety of applications (Nathan et al., 1992; Nathan et al., 1993).

[0099] The term "gene" refers to a DNA sequence that comprises control and coding

sequences necessary for the production of a polypeptide or precursor thereof. The polypeptide can be encoded by a full length coding sequence or by any portion of the coding sequence so long as the desired enzymatic activity is retained.

[0100] The term "subject" refers to animals, including humans.

[0101] The term "wild-type" refers to a gene or gene product which has the characteristics of that gene or gene product when isolated from a naturally occurring source. A wild-type gene is that which is most frequently observed in a population and is thus arbitrarily designated the "normal" or "wild-type" form of the gene. In contrast, the term "modified" or "variant" or "mutant" refers to a gene or gene product which displays modifications in sequence and or functional properties (i.e., altered characteristics) when compared to the wild-type gene or gene product. It is noted that naturally-occurring mutants can be isolated; these are identified by the fact that they have altered characteristics when compared to the wild-type gene or gene product.

VIII. Kits

[0102] The pharmaceutical compositions and combinations of for use according to the present disclosure may be provided as kits, such as therapeutic kits. For example, a kit may comprise one or more pharmaceutical composition as described herein and optionally instructions for their use. Kits may also comprise one or more devices for accomplishing administration of such compositions. For example, a subject kit may comprise a pharmaceutical composition and catheter for accomplishing direct intravenous injection of the composition into a cancerous tumor. In other embodiments, a subject kit may comprise pre-filled ampoules of a stabilized multimeric arginase or isolated pegylated arginase, optionally formulated as a pharmaceutical, or lyophilized, for use with a delivery device.

[0103] Kits may comprise a container with a label. Suitable containers include, for example, bottles, vials, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container may hold a composition which includes an antibody that is effective for therapeutic or non-therapeutic applications, such as described above. The label on the container may indicate that the composition is used for a specific therapy or non-therapeutic application, and may also indicate directions for either in vivo or in vitro use, such as those described above. The kit of the invention will typically comprise the container described above and one or more other containers comprising materials desirable from a commercial and user standpoint, including buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.

IX. EXAMPLES

[0104] The following examples serve to illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof. In the experimental disclosure which follows, the following abbreviations apply: eq (equivalents); M (Molar); μM (micromolar); mM (millimolar); N (Normal); mol (moles); mmol (millimoles); μmol (micromoles); nmol (nanomoles); g (grams); mg (milligrams); μg (micrograms); L (liters); ml (milliliters); μl (microliters); cm (centimeters); mm (millimeters); μm (micrometers); nm (nanometers); EC (degrees Centigrade); MW (molecular weight); PBS (phosphate buffered saline); min (minutes).

Example 1

Incorporating and Determining Metal Content in Arginase I

[0105] Incorporation of Mn^{2+} and Co^{2+} can be achieved by purifying arginase, followed by an incubation step with 10 mM metal at 50° C. for 10 minutes. In order to determine the final metal content and identity of the arginase preparations, protein samples of Mn-hArgI (145 μM), Co-hArgI (182 μM) and associated dialysis buffers (100 M HEPES, pH 7.4) were diluted in 2% nitric acid and analyzed by inductively coupled plasma mass spectrometry (ICP-MS, Department of Geological Sciences, University of Texas at Austin) to quantify the protein's cobalt, iron, manganese and zinc content by subtracting the concentration of metals found in the dialysis buffer from the metal concentration of the final protein samples and dividing by protein concentration. To determine protein concentrations, an extinction coefficient was calculated for hArgI based on the amino acid sequence (Gill and von Hippel, 1989). All protein concentrations for Arginase I were calculated based upon the calculated $\epsilon_{280}=24,180 \text{ M}^{-1} \text{ cm}^{-1}$ in a final buffer concentration of 6 M guanidinium hydrochloride, 20 mM phosphate buffer, pH 6.5. For comparison, arginase concentration was also calculated by BCA assay using dilutions of BSA as a standard. Using this method it was found that arginase samples incubated with Co^{2+} contain 2.1 ± 0.5 equivalents Co and 0.4 ± 0.1 equivalents Fe, with no detectable amounts of Zn or Mn. Samples incubated with Mn^{2+} contain 1.5 ± 0.2 equivalents Mn and 0.4 ± 0.1 equivalents Fe, and no detectable amounts of Zn or Co. Thus, heat incubation is an efficient method for incorporation of cobalt.

[0106] Additional studies of cobalt loading have demonstrated that a higher proportion of cobalt loading is achievable and results in a higher specific activity. The results of these studies is shown on the following table and in Fig.3.

TABLE 2

Co-Arginase I Cobalt Loading						
Identity	Co (mM)	Temp (°C)	Time (Min)	Total Co (µg/mg Arginase)	Total Mn (µg/mg Arginase)	Specific Activity (U/mg)
APO-Arginase I*	NA	NA	NA	<0.025	0.008	24
APO Loading 1*	0.1	5	15	0.3	ND	117
Coh-Arg I*	10	20	60	2	0.06	410
APO Loading 2*	1	5	15	2.4	ND	395
APO Loading 3*	10	20	15	2.8	ND	493
APO Loading 4*	10	20	60	2.9	ND	489
APO Loading 5	10	37	15	2.8	ND	NT
APO Loading 6	10	53	15	2.6	ND	NT
Co-ArgI-PEG	10	53	15	3	ND	500
Theoretical				3.4		
* Graphed						

[0107] The starred data are shown in Fig. 3.

Example 2

Cytotoxicity of Co-Arg and its Variants Towards Hepatocellular Carcinoma Cells and Metastatic Melanomas

[0108] In order to test the in vitro cytotoxicity of engineered arginase, varying concentrations (0-100 nM) of Mn-ArgI, Co-ArgI, or Co-hArgI variants were incubated with HCC (Hep 3b) cells or melanoma (A375) cells (American Type Culture Collection) in 96-well plates at a seeding density of 500 cells/well, in DMEM media supplemented with fetal bovine serum. After 24 hours of incubation at 37° C, the cells were treated with arginase containing media in triplicate at various concentrations. The control solution was a balanced salt solution in media. The treated cells were maintained at 37° C and 5% CO₂. Cells were tested by standard MTT assay (Sigma-

Aldrich) on days 1, 3, 5, & 7 by addition of 100 μL /well of MTT (5 mg/mL), and incubated for 4 hours with gentle agitation one to two times per hour. Following this, the solution was aspirated and 200 μL of DMSO was then added to each well. Absorbance at 570 nm was interpreted for each well using an automated plate reader to determine the relative number of surviving cells compared to controls. The resulting data was fit to an exponential equation to determine an apparent IC_{50} value for arginase cytotoxicity. The IC_{50} values from day 5 were calculated, yielding an IC_{50} value for Mn-hArgI of 5 ± 0.3 nM (~ 0.18 $\mu\text{g}/\text{ml}$) and a value of 0.33 ± 0.02 nM for Co-hArgI (~ 0.012 $\mu\text{g}/\text{ml}$). Thus, the Co-ArgI enzyme appears to be 15 fold more cytotoxic than the Mn substituted enzyme against HCC. Against the metastatic melanoma cell line (A375) Mn-hArgI resulted in an apparent IC_{50} of 4.1 ± 0.1 nM (~ 0.15 $\mu\text{g}/\text{ml}$). Incubation with Co-hArgI lead to a 13-fold increase in cytotoxicity with an apparent IC_{50} of 0.32 ± 0.06 nM (~ 0.012 $\mu\text{g}/\text{ml}$).

Example 3

Engineering an Fc-Arginase Fusion Protein for Enhanced In Vivo Half-Life

[0109] Fusion to the IgG Fc domain has been employed extensively for prolonging the in vivo half-lives of therapeutic polypeptides such as the TNF- α inhibitor etanercept (EnbrilTM). The Fc domain binds to the Fc γ Rn receptor, which is expressed on vascular endothelium and many other tissues (Roopenian and Akilesh, 2007). The affinity of Fc γ Rn for the IgG Fc domain is strongly pH dependent. Binding occurs at the acidic pH of endosomal compartments allowing the protein to be recycled onto the cell surface and thus escape proteolytic degradation. At the cell surface, the Fc domain is released from Fc γ Rn because the binding affinity is very low at physiological pH. Endosomal recycling via Fc γ Rn is estimated to increase the serum half-life of immunoglobulins at least 4-7 fold, to about 7-14 days in humans. Fc fusions exploit this property to endow short lived molecules with a long half-life. However, the human arginase is a homotrimer and therefore if fused to the IgG Fc, which itself is a dimer, the resulting Fc-arginase polypeptide will likely form high molecular weight aggregates.

[0110] This problem was avoided by employing mutant forms of arginase that disrupt trimerization and are stable in the monomeric form. The trimerization and subunit interface of Arginase I have been studied in some detail (Lavulo et al., 2001). A single amino acid substitution at Glu256Gln has been shown to disrupt trimerization resulting in the formation of monomeric Arginase I enzyme (Sabio et al., 2001). After expression and purification of this variant, the steady-state kinetic analysis revealed nearly identical activity compared to Co-hArgI with a $k_{\text{cat}}/K_{\text{M}}$ of $1,320$ s^{-1} mM^{-1} .

[0111] This construct was then cloned into Fc expression vectors. The Fc expression vector is a construct based on a pTRC99a plasmid (Amersham) that contains a DsbA leader sequence followed by the IgG Fc coding region, an EcoRI restriction site and a stop codon. The

monomeric arginase gene was placed in frame behind the Fc coding region by digesting both vector and gene with EcoRI, and was subsequently ligated and transformed into *E. coli* (BL21) for sequencing and expression. Since the IgG Fc is normally a glycosylated protein, expression of recombinant IgGs or of Fc fusions has so far been carried out in recombinant mammalian cells that, unlike bacteria, are capable of N-linked glycosylation. However, while glycosylation at Asn297 is critical for the binding to the activating and inhibitory Fc γ receptors (Fc γ RI-III in humans) it does not have a noticeable effect on the affinity or pH dependent binding to Fc γ Rn (Tao and Morrison, 1989; Simmons et al., 2002). Thus, aglycosylated IgG antibodies expressed in bacteria exhibit serum persistence in primates nearly indistinguishable from that of fully glycosylated antibodies expressed in mammalian cells (Simmons et al., 2002). In contrast to prevailing earlier notions, IgG antibodies and Fc proteins can be expressed efficiently in *E. coli* up to g/L levels in fermenters. *E. coli* expression is technically much simpler and faster. In addition, since the resulting protein is aglycosylated, it does not display glycan heterogeneity, an important issue in the expression of therapeutic glycoproteins (Jefferis, 2007). The fusion protein is purified by Protein A chromatography and the yield of correctly folded, dimeric Fc-arginase fusion relative to polypeptides that fail to dimerize is quantified by FPLC gel filtration chromatography. This formulation has led to a highly active and very stable form of human arginase, suitable for in vivo trials.

Example 4

Pegylation of Arginase

[0112] Arginase was purified and was then made 10 mM with CoCl₂ and heated at 50° C for 10 minutes. After centrifuging to remove any precipitates, the PEG-5000 arginase was extensively buffer exchanged (PBS with 10% glycerol) using a 100,000 MWCO filtration device (Amicon), and sterilized with a 0.2 micron syringe filter (VWR). All pegylated enzyme was analyzed for lipopolysaccharide (LPS) content using a Limulus Amebocyte Lysate (LAL) kit (Cape Cod Incorporated).

[0113] Pegylated Co-hArgI was found to have nearly identical serum stability to wild type enzyme and displayed a k_{cat}/K_M value of $1690 \pm 290 \text{ s}^{-1} \text{ mM}^{-1}$.

Example 5

Serum Depletion of L-Arg in the Mouse Model

[0114] Balb/c mice were treated by single IP injection with 500 μg of pharmacologically

prepared, pegylated Co-hArgI or an equal volume of PBS. Mice were sacrificed by cardiac venipuncture for blood collection at the time points of 0, 48, 72, and 96 hrs. Blood samples were immediately mixed 50:50 (v/v) with a 400 mM sodium citrate buffer pH 4, allowed to clot for 30 minutes and centrifuged for serum separation. The resulting serum was then filtered on a 10,000 MWCO device (Amicon) for the removal of large proteins and precipitates and the flow-through was collected for analysis. L-arginine standards, control mouse serum and experimental samples were derivatized with OPA (Agilent) and separated on a C18 reverse phase HPLC column (Agilent) (5 μ m, 4.6 \times 150 mm) essentially as described by Agilent Technologies (Publication Number: 5980-3088) except for modification of the separation protocol slightly by reducing the flow rate by 1/2 and doubling the acquisition time to get better peak separation. An L-arginine standard curve was constructed by plotting L-Arg peak area versus concentration in order to quantify serum L-Arg levels. A single dose of pharmacologically prepared Co-hArgI was sufficient to keep L-Arg at or below detection limits for over 3 days (FIG. 1).

Example 6

HCC Tumor Xenograft Treatment with Co-hArgI

[0115] Nude mice were injected subcutaneously in the flank with $\sim 10^6$ HCC cells collected from a 75% confluent tissue culture. After the HCC xenografted tumors had grown to ~ 0.5 cm³ in diameter (Day 9), mice were sorted into two groups. The experimental group received a 500 μ g IP injection of pharmacologically optimized Co-hArgI at day 9 and at day 12. The control group received IP injections of PBS at days 9 and 12. As can be seen in FIG. 2, the PBS treated tumors had increased 3-fold in size by day 15. In stark contrast, Co-hArgI treated tumors had decreased in size by day 15. Mn-hArgI treated tumors had only been shown to be retarded in growth rate (Cheng et al., 2007). Co-hArgI appears to be a highly effective chemotherapeutic agent against HCCs both in vitro and in vivo.

Example 7

Disruption of the L-Arginine Balance in the Tumor Microenvironment with Co-hArgI and anti-PD-L1 Ab

[0116] Human arginase I (hArgI) is a Mn²⁺-dependent enzyme that displays low activity and low stability in serum. Myeloid-derived suppressor cells (MDSC) express hArgI and nitric-oxide synthase (NOS), which control the availability of L-arginine in the tumor microenvironment and in turn regulate the function of T-cells. Depletion of L-arginine by MDSC has been correlated to

impairment of T-cell anti-tumor function and tumor evasion of host immunity. The expression of enzymes of the L-arginine biosynthetic pathway in peripheral blood mononuclear cells, bone marrow mononuclear cells and CD34⁺ cells was analyzed revealing that these cells express low levels of OTC and ASS, suggestive of dependence of these cells on exogenous/extracellular L-arginine for physiological function. Based on this finding it is contemplated that long term depletion of L-arginine may negatively impact the MDSC population and therefore enhance immune regulation of tumor growth. This hypothesis was tested using engineered hArgI (AEB1102), developed by replacement of the Mn²⁺ natural cofactor with Co²⁺ which results in significantly improved catalytic activity and serum stability compared to endogenous hArgI. The engineered enzyme is also pegylated as described above. The effects of chronic, extensive pegylated Co-hArgI-mediated depletion of L-arginine *in vivo* in the murine CT26 colon-cancer model dosed alone and in combination with anti-PD-L1 and anti-PD-1 monoclonal antibodies (mAbs) were tested.

[0117] Female Envigo Balb/c mice (BALB/cAnNHsd) were used in these studies. They were 6-7 weeks old on Day 1 of the test. Test animals were implanted subcutaneously on Day 0 with 5.0E+05 CT26.WT cells. All mice were sorted into study groups and treatment was started as follows:

AEB-001-1037

- Group 1: Vehicle (PBS) IP, Q7Dx4; plus Isotype Control, 10mg/kg IP, (Q3Dx2; 3off)x4
- Group 2: AEB1102, (3mg/kg IP, Q7Dx4)
- Group 3: anti-PD-L1 Ab, 10mg/kg IP, (Q3Dx2; 3off)x4
- Group 4: AEB1102, 3mg/kg IP, Q7Dx4; plus anti-PD-L1 Ab, 10mg/kg IP, (Q3Dx2; 3off)x4;

[0118] AEB1102 was dosed 4 times, once weekly, (Days 3, 10, 17, 24)

[0119] Anti-PD-L1 was dosed 8 times, one on two off, one on three off each week (Days 3, 6, 10, 13, 17, 20, 24, 27)

[0120] All animals were observed for clinical signs at least once daily. Individual body weights and tumor volumes were recorded three times weekly. Individual mice were terminated when tumor size reached a value of 2000 mm³.

[0121] *In vivo* treatment of CT26 mice with AEB1102 (pegylated Co-hArgI) resulted in a therapeutic effect comparable to standard immunomodulatory antibodies that target PD-1 and PD-L1. Of significance, combination therapy of AEB1102 with anti-PD-1 and PD-L1 mAbs resulted in an apparently synergistic or at least additive anti-tumor effect compared to AEB1102 alone and immunotherapy alone.

[0122] The data from this study is shown graphically in Fig. 4. The data reflect the effect of treatment with a pegylated Co-hArgI in combination with an anti-immune checkpoint protein

receptor (anti-PD-1) and ligand, (anti-PD-L1). In the figure the upper curve is an isotype control antibody, the second curve is anti-PD-L1 antibody, the third curve is pegylated Co-hArgI and the lowest curve is the combination treatment of the pegylated Co-hArgI and anti-PD-L1 antibody. As seen in the data, the combination of the 2 agents has a greater than additive effect on inhibition of tumor growth.

[0123] The effect on lymphocyte Tcell activation was also measured in samples taken on day 3. The percentage of total live cells that expressed CD45+ in the four groups as well as the percentage of CD45+ cells that were also CD8+ are shown in Table 3. These data are also shown in graphical form in Figs. 6 and 7.

Table reports mean \pm SEM

Groups	Day 3 CD45+ cells	Day 3 CD8+ cells
Vehicle	14.8 \pm 3.4	19.4 \pm 3.9
Isotype	13.8 \pm 2.2	18.7 \pm 2.1
AEB1102	26.5 \pm 3.7	18.7 \pm 7.1
anti-PD-LI	13.1 \pm 3.5	26.3 \pm 3.24
AEB1102 + anti-PD-LI	22.4 \pm 2.3	34.2 \pm 5.0

[0124] Collectively these results demonstrate that disrupting the L-arginine physiological balance in the tumor microenvironment inhibits tumor growth and further sensitizes the tumor to immunotherapy.

Example 8

Effect of treatment of Colon Carcinoma Treatment with ArgI and OX40

[0125] Suspensions of MC38 colon carcinoma cells were injected into the flanks of female C57BL/6 mice. When tumor volume reached 75-100 mm³ on day 0, mice were randomized into groups. Tumor volume was measured twice a week using calipers. Treatments were started on Day 0.

[0126] A first group was injected with 10 mg/kg isotype control biweekly for 6 weeks, second group was injected with 3 mg/kg co-Arginase I, weekly for 6 weeks, a third group was injected with 10 mg/kg anti-OX40ab weekly for 6 weeks, and a fourth group was injected with 3 mg/kg co- ArgI and 10 mg/kg anti OX40ab weekly for 6 weeks. The data from this study is shown in Fig. 5. Although it appears that the co-ArgI was given at a suboptimal dose, a trend is seen in which the combination of ArgI and aOX40 has a more than additive effect on the reduction or

inhibition of tumor volume.

REFERENCES

[0127] The following reference, to the extent that it provides exemplary procedural or other details supplementary to those set forth herein, is given.

Cama et al., *Biochemistry*, 42:7748-7758, 2003.

Cheng et al., *Cancer Lett.*, 224:67-80, 2005.

Cheng et al., *Cancer Res.*, 67:309, 2007.

Cheng et al., *Cancer Res.*, 67:4869-4877, 2007.

Dillon et al., *Med. Sci. Monit.*, 8:BR248-253, 2002.

Dowling et al., *Cell Mol. Life. Sci.*, 65(13):2039-55, 2008.

Durante et al., *Clin. Exp. Pharmacol. Physiol.*, 34:906-911, 2007.

Ensor et al., *Cancer Res.*, 62:5443-5450, 2002.

Feun et al., *J. Neurooncol.*, 82:177-181, 2007.

Gill and von Hippel, *Anal. Biochem.*, 182:319-326, 1989.

Greenwald et al., *Crit. Rev Therap Drug Carrier Syst.*, 17:101-161, 2000.

Harkki et al., *BioTechnology*, 7:596-603, 1989.

Harris et al., *Clin. Pharmacokinet.*, 40(7):539-51, 2001.

Hopwood et al., In: *Genetic Manipulation of Streptomyces, A Laboratory Manual*, The John Innes Foundation, Norwich, Conn., 1985.

Izzo et al., *J. Clin. Oncol.*, 22:1815-1822, 2004.

Jefferis, *Expert Opin. Biol. Ther.*, 7:1401-1413, 2007.

Lavulo et al., *J. Biol. Chem.*, 276:14242-14248, 2001.

Lopez et al., *Febs J.*, 272:4540-4548, 2005.

Lordanescu, *J. Bacteriol*, 12:597 601, 1975.

Mellor et al., *Gene*, 24:1-14, 1983.

Nathan et al., *Bioconj Chem.*, 4:54-62, 1993.

- Nathan et al., *Macromolecules*, 25:4476-4484, 1992.
- Pardoll, Drew, *Nature Reviews Cancer* 12, 252-264 (April 2012)
- Penttila et al., *Gene*, 61:155-164, 1987.
- Remington's *Pharmaceutical Sciences*, 18th Ed. Mack Printing Company, 1289-1329, 1990.
- Roopenian and Akilesh, *Nat. Rev. Immunol.*, 7:715-725, 2007.
- Sabio et al., *FEBS Lett.*, 501:161-165, 2001.
- Santhanam et al., *Circ. Res.*, 101:692-702, 2007.
- Savoca et al., *Cancer Biochem. Biophys.*, 7:261-268, 1984.
- Scott et al., *Br. J. Cancer*, 83:800-810, 2000.
- Shen et al., *Cancer Lett.*, 231:30-35, 2006.
- Sibakov et al., *Eur. J. Biochem.*, 145:567-572, 1984.
- Simmons et al., *J. Immunol. Methods*, 263:133-147, 2002.
- Tao et al., *J. Immunol.*, 143:2595-2601, 1989.
- Ward, *Embo-Alko Workshop on Molecular Biology of Filamentous Fungi*, Helsinki, 119-128, 1989.
- Wheatley and Campbell, *Pathol. Oncol. Res.*, 8:18-25, 2002.
- Yoon et al., *Int. J. Cancer*, 120:897-905, 2007.
- Zalipsky et al., *Bioconjug Chem.*, 8:111-118, 1997.

REFERENCES CITED IN THE DESCRIPTION

Cited references

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [US8440184B](#) [0019]

Non-patent literature cited in the description

- Remington's Pharmaceutical Sciences19900000 [0076] [0077] [0078]
- CAMA et al.Biochemistry, 2003, vol. 42, 7748-7758 [0127]
- CHENG et al.Cancer Lett., 2005, vol. 224, 67-80 [0127]
- CHENG et al.Cancer Res., 2007, vol. 67, 309- [0127]
- CHENG et al.Cancer Res., 2007, vol. 67, 4869-4877 [0127]
- DILLON et al.Med. Sci. Monit., 2002, vol. 8, BR248-253 [0127]
- DOWLING et al.Cell Mol. Life. Sci., 2008, vol. 65, 132039-55 [0127]
- DURANTE et al.Clin. Exp. Pharmacol. Physiol., 2007, vol. 34, 906-911 [0127]
- ENSOR et al.Cancer Res., 2002, vol. 62, 5443-5450 [0127]
- FEUN et al.J. Neurooncol., 2007, vol. 82, 177-181 [0127]
- GILLVON HIPPELAnal. Biochem., 1989, vol. 182, 319-326 [0127]
- GREENWALD et al.Crit. Rev Therap Drug Carrier Syst., 2000, vol. 17, 101-161 [0127]
- HARKKI et al.BioTechnology, 1989, vol. 7, 596-603 [0127]
- HARRIS et al.Clin. Pharmacokinet., 2001, vol. 40, 7539-51 [0127]
- HOPWOOD et al.Genetic Manipulation of Streptomyces, A Laboratory ManualThe John Innes Foundation19850000 [0127]
- IZZO et al.J. Clin. Oncol., 2004, vol. 22, 1815-1822 [0127]
- JEFFERISExpert Opin. Biol. Ther., 2007, vol. 7, 1401-1413 [0127]
- LAVULO et al.J. Biol. Chem., 2001, vol. 276, 14242-14248 [0127]
- LOPEZ et al.Febs J., 2005, vol. 272, 4540-4548 [0127]
- LORDANESCUJ. Bacteriol, 1975, vol. 12, 597-601 [0127]
- MELLOR et al.Gene, 1983, vol. 24, 1-14 [0127]
- NATHAN et al.Bioconj Chem., 1993, vol. 4, 54-62 [0127]
- NATHAN et al.Macromolecules, 1992, vol. 25, 4476-4484 [0127]
- PARDOLL, DREWNature Reviews Cancer, 2012, vol. 12, 252-264 [0127]
- PENTTILA et al.Gene, 1987, vol. 61, 155-164 [0127]
- Remington's Pharmaceutical SciencesMack Printing Company199000001289-1329 [0127]
- ROOPENIANAKILESHNat. Rev. Immunol., 2007, vol. 7, 715-725 [0127]
- SABIO et al.FEBS Lett., 2001, vol. 501, 161-165 [0127]
- SANTHANAM et al.Circ. Res., 2007, vol. 101, 692-702 [0127]
- SAVOCA et al.Cancer Biochem. Biophys., 1984, vol. 7, 261-268 [0127]

- **SCOTT et al.** Br. J. Cancer, 2000, vol. 83, 800-810 [0127]
- **SHEN et al.** Cancer Lett., 2006, vol. 231, 30-35 [0127]
- **SIBAKOV et al.** Eur. J. Biochem., 1984, vol. 145, 567-572 [0127]
- **SIMMONS et al.** J. Immunol. Methods, 2002, vol. 263, 133-147 [0127]
- **TAO et al.** J. Immunol., 1989, vol. 143, 2595-2601 [0127]
- **WARDE** Embo-Alko Workshop on Molecular Biology of Filamentous Fungi, Helsinki, 1989, 119-128 [0127]
- **WHEATLEY CAMPBELL** Pathol. Oncol. Res., 2002, vol. 8, 18-25 [0127]
- **YOON et al.** Int. J. Cancer, 2007, vol. 120, 897-905 [0127]
- **ZALIPSKY et al.** Bioconj Chem., 1997, vol. 8, 111-118 [0127]

PATENTKRAV

1. Farmaceutisk sammensætning, der omfatter et humant arginase I-enzym, der omfatter en koboltkofaktor, og et immunonkologisk middel til anvendelse i en fremgangsmåde til inhibering af tumorvækst hos et individ, hvor det immunonkologiske middel er valgt fra gruppen bestående af et anti-PD-1-antistof, et anti-PD-L1-antistof, et anti-OX40-antistof og et anti-OX40L-antistof.

2. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor tumoren omfatter argininauxotrofe tumorceller; fortrinsvis hvor tumoren udviser en reduceret eller inhiberet ekspression af argininsuccinatsynthetase, ornithintranscarbamyase, argininsuccinatlyase eller en kombination deraf.

3. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor det humane arginase I-enzym stabiliseres ved association med en polyætylenglykol eller konjugation til en syntetisk proteinpolymer, et Fc-fragment eller albumin.

4. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor det humane arginase I-enzym er pegyleret.

5. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor individet er et dyr eller en menneskelig cancerpatient.

6. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor det immunonkologiske middel omfatter pembrolizumab, atezolizumab eller nivolumab.

7. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor tumoren er et hepatocellulært karcinom, et nyrecellekarcinom, en brystcancer, et melanom, en prostatacancer, en bugspytkirtelcancer, en blærecancer, et kolonkarcinom, en kolorektal cancer, en tredobbelt negativ brystcancer, et Hodgkins lymfom, en mavecancer, et glioblastom, et Merkelcellekarcinom, et lungekarcinom, en småcellet lungecancer eller en ikke-småcellet lungecancer.

8. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor i fremgangsmåden til inhibering af tumorvækst i et individ enten:

det humane arginase I-enzym og anti-PD-1-antistoffet, anti-PD-L1-antistoffet, anti-OX40-antistoffet eller anti-OX40L-antistoffet indgives samtidigt; eller

det humane arginase I-enzym og anti-PD-1-antistoffet, anti-PD-L1-antistoffet, anti-OX40-antistoffet eller anti-OX40L-antistoffet indgives sekventielt.

9. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1

til 8, hvor det humane arginase I-enzym udviser en k_{cat}/K_M til hydrolyse af arginin mellem $400 \text{ mM}^{-1} \text{ s}^{-1}$ og $4.000 \text{ mM}^{-1} \text{ s}^{-1}$ ved pH 7,4 og $37 \text{ }^\circ\text{C}$; eller

det humane arginase I-enzym omfatter et forhold mellem kobolt og arginase fra 2 til $3 \mu\text{gCo}/\text{mg}$ arginase; eller

5 det humane arginase I-enzym kan opnås ved at bringe et arginase-apoenzym i kontakt med kobolt eller en koboltion ved en temperatur fra $30 \text{ }^\circ\text{C}$ til $55 \text{ }^\circ\text{C}$ i en periode fra 15 minutter til 60 minutter.

10 **10.** Kombination til anvendelse i behandlingen af cancer hos en cancerpatient, hvor kombinationen omfatter en farmaceutisk sammensætning, der omfatter et pegyleret humant arginase I-enzym, der omfatter en koboltkofaktor, og en immunsystemmodulerende terapi, der omfatter en farmaceutisk sammensætning, der omfatter et immunonkologisk middel, der er valgt blandt et anti-PD-1-antistof, et anti-PD-L1-antistof, et anti-OX40-antistof eller et anti-OX40L-antistof, hvor:

15 den farmaceutiske sammensætning, der omfatter et pegyleret humant arginase I-enzym, der omfatter en koboltkofaktor, og den farmaceutiske sammensætning, der omfatter det immunonkologiske middel, indgives samtidigt; eller

den farmaceutiske sammensætning, der omfatter et humant arginase I-enzym, der omfatter en koboltkofaktor, og den farmaceutiske sammensætning, der omfatter et immunonkologisk middel, indgives sekventielt.

20 **11.** Kombination til anvendelse ifølge krav 10, hvor en terapeutisk mængde af det pegylerede humane arginase I-enzym, der omfatter en koboltkofaktor, er fra $0,01 \text{ mg}/\text{kg}$ til $7,5 \text{ mg}/\text{kg}$ eller fra $0,05 \text{ mg}/\text{kg}$ til $5 \text{ mg}/\text{kg}$ eller fra $0,1 \text{ mg}/\text{kg}$ til $5 \text{ mg}/\text{kg}$.

12. Kombination til anvendelse ifølge krav 10 eller krav 11, hvor det immunonkologiske middel er valgt blandt pembrolizumab, atezolizumab og nivolumab.

25 **13.** Kombination til anvendelse ifølge et hvilket som helst af kravene 10 til 12, hvor cancerpatienten behandles for hepatocellulært karcinom, nyrecellekarcinom, brystcancer, melanom, prostatacancer, bugspytkirtelcancer, blærecancer, kolonkarcinom, kolorektal cancer, tredobbelt negativ brystcancer, Hodgkins lymfom, mavecancer, glioblastom, Merkelcellekarcinom, lungekarcinom, småcellet lungecancer eller ikke-småcellet lungecancer.

30 **14.** Kombination til anvendelse ifølge et hvilket som helst af kravene 10 til 13, hvor den farmaceutiske sammensætning, der omfatter et pegyleret humant arginase I-enzym, der omfatter en koboltkofaktor, indgives parenteralt eller indgives topisk, intravenøst, intradermalt, intraarterielt, intraperitonealt, intralæsielt, intrakranielt, intraartikulært, intraprostatisk, intrapleuralt, intratrakealt, intraokulært, intranasalt, intravitrealt, intravaginalt, intrarektalt,

intramuskulært, subkutant, subkonjunktivalt, intravesikulært, via slimhinde, intraperikardialt, intraumbilisk, oralt, ved inhalation, ved injektion, ved infusion, ved kontinuerlig infusion, ved lokal perfusion, der direkte bader målceller, via et kateter eller via en lavement.

DRAWINGS




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7